ATE251902T1 - Pharmazeutische zusammensetzung zur reduzierung der mcp-1 proteinsynthese - Google Patents

Pharmazeutische zusammensetzung zur reduzierung der mcp-1 proteinsynthese

Info

Publication number
ATE251902T1
ATE251902T1 AT98943862T AT98943862T ATE251902T1 AT E251902 T1 ATE251902 T1 AT E251902T1 AT 98943862 T AT98943862 T AT 98943862T AT 98943862 T AT98943862 T AT 98943862T AT E251902 T1 ATE251902 T1 AT E251902T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
protein synthesis
reducing mcp
mcp
reducing
Prior art date
Application number
AT98943862T
Other languages
English (en)
Inventor
Angelo Guglielmotti
Alberto Mantovani
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Application granted granted Critical
Publication of ATE251902T1 publication Critical patent/ATE251902T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98943862T 1997-07-28 1998-07-22 Pharmazeutische zusammensetzung zur reduzierung der mcp-1 proteinsynthese ATE251902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001789A IT1293795B1 (it) 1997-07-28 1997-07-28 Farmaco attivo nel ridurre la produzione di proteina mcp-1
PCT/EP1998/004924 WO1999004770A2 (en) 1997-07-28 1998-07-22 A pharmaceutical composition active in reducing production of mcp-1 protein

Publications (1)

Publication Number Publication Date
ATE251902T1 true ATE251902T1 (de) 2003-11-15

Family

ID=11377642

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98943862T ATE251902T1 (de) 1997-07-28 1998-07-22 Pharmazeutische zusammensetzung zur reduzierung der mcp-1 proteinsynthese

Country Status (16)

Country Link
US (1) US6534534B1 (de)
EP (1) EP1005332B1 (de)
JP (2) JP4651191B2 (de)
AR (1) AR016382A1 (de)
AT (1) ATE251902T1 (de)
AU (1) AU744492B2 (de)
CA (1) CA2300289C (de)
DE (1) DE69819012T2 (de)
DK (1) DK1005332T3 (de)
ES (1) ES2207858T3 (de)
HK (1) HK1028561A1 (de)
IT (1) IT1293795B1 (de)
PT (1) PT1005332E (de)
SI (1) SI1005332T1 (de)
WO (1) WO1999004770A2 (de)
ZA (1) ZA986636B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
HUE026910T2 (en) * 2008-03-07 2016-07-28 Acraf 1-Benzyl-3-hydroxymethylindazole derivatives and their use in the treatment of MCP-1 and CX3CR1 expression-based diseases
PL2254869T3 (pl) * 2008-03-07 2017-10-31 Acraf Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40
PL2262778T3 (pl) * 2008-03-07 2020-02-28 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CXCR1 i p40
KR101736301B1 (ko) 2009-08-03 2017-05-29 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 1-벤질-3-하이드록시메틸-1ｈ-인다졸 및 이의 유도체 및 필요한 마그네슘 중간체들의 제조 방법
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
EP2539710A4 (de) 2010-02-25 2016-07-06 Prairie Ventures Llc System und verfahren zur handhabung, lagerung und analyse anatomischer krankheitserregerproben
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
JP6944442B2 (ja) 2015-06-12 2021-10-06 ベットーレ リミテッド ライアビリティー カンパニーＶｅｔｔｏｒｅ， Ｌｌｃ 疾患を治療するためのｍｃｔ４阻害剤
WO2018111904A1 (en) 2016-12-12 2018-06-21 Vettore, LLC Heterocyclic inhibitors of mct4
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
AU5537994A (en) 1992-10-22 1994-05-09 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
JPH08333262A (ja) * 1995-04-07 1996-12-17 Chugai Pharmaceut Co Ltd 免疫抑制剤
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19538402A1 (de) * 1995-10-14 1997-04-17 Boehringer Mannheim Gmbh Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel
JPH09165339A (ja) * 1995-10-27 1997-06-24 American Home Prod Corp ラパマイシンを付与したドナー脾細胞を用いる臓器移植の延長
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1

Also Published As

Publication number Publication date
SI1005332T1 (en) 2004-02-29
DE69819012D1 (de) 2003-11-20
DK1005332T3 (da) 2004-02-09
JP2001510793A (ja) 2001-08-07
IT1293795B1 (it) 1999-03-10
ES2207858T3 (es) 2004-06-01
WO1999004770A3 (en) 1999-04-15
CA2300289C (en) 2007-11-20
PT1005332E (pt) 2004-03-31
JP2010047609A (ja) 2010-03-04
AR016382A1 (es) 2001-07-04
US6534534B1 (en) 2003-03-18
JP5086322B2 (ja) 2012-11-28
HK1028561A1 (en) 2001-02-23
DE69819012T2 (de) 2004-08-12
EP1005332A2 (de) 2000-06-07
ITMI971789A1 (it) 1999-01-28
WO1999004770A2 (en) 1999-02-04
ZA986636B (en) 1999-02-04
CA2300289A1 (en) 1999-02-04
AU744492B2 (en) 2002-02-28
AU9160198A (en) 1999-02-16
JP4651191B2 (ja) 2011-03-16
EP1005332B1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
ID27415A (id) Komposisi farmaseutik
DE69807420D1 (de) Pharmazeutische aerosolzusammensetzung
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
FI955311A (fi) Farmaseuttinen koostumuspohja
ID29262A (id) Komposisi farmasi
ID27201A (id) Komposisi farmasi
ATE251902T1 (de) Pharmazeutische zusammensetzung zur reduzierung der mcp-1 proteinsynthese
ATE273697T1 (de) Pharmazeutische levothyroxinzubereitung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ID29294A (id) Komposisi farmasi
ATE208364T1 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
ID25857A (id) Komposisi farmasi
ID18698A (id) Komposisi farmasi
ID26215A (id) Komposisi farmasi
ITMI962628A0 (it) Composizione farmaceutica
ID23531A (id) Komposisi farmasi
BR1100755A (pt) composição farmacêutica
BR1101151A (pt) Compostos e composição farmacêutica
SE9601854D0 (sv) Farmaceutisk komposition
ID17133A (id) Komposisi farmasi
SE9604299D0 (sv) Pharmaceutical composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1005332

Country of ref document: EP